Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor‐Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy

BACKGROUND: The combination of everolimus (EVE) and exemestane (EXE) is approved for the treatment of patients with metastatic hormone receptor‐positive breast cancer (mHRBC) who progress on nonsteroidal aromatase inhibitor (NSAI) therapy. However, none of the patients enrolled in the trial that led...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncologist
Huvudupphovsmän: Cook, Madeline M., Al Rabadi, Luai, Kaempf, Andy J., Saraceni, Megan M., Savin, Michael A., Mitri, Zahi I.
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley & Sons, Inc. 2020
Ämnen:
Breast Cancer
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7873317/
https://ncbi.nlm.nih.gov/pubmed/33230905
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13609
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk